Home Cart Sign in  
Chemical Structure| 130798-51-5 Chemical Structure| 130798-51-5

Structure of MDL-29951
CAS No.: 130798-51-5

Chemical Structure| 130798-51-5

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

MDL-29951 is a glycine antagonist of NMDA receptor activation (Ki=0.14 mM, [3H]glycine binding) in vitro and in vivo.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of MDL-29951

CAS No. :130798-51-5
Formula : C12H9Cl2NO4
M.W : 302.11
SMILES Code : O=C(C(N1)=C(CCC(O)=O)C2=C1C=C(Cl)C=C2Cl)O
MDL No. :MFCD00897722
InChI Key :KNBSYZNKEAWABY-UHFFFAOYSA-N
Pubchem ID :446916

Safety of MDL-29951

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H317
Precautionary Statements:P280-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
Human astrocytoma cells 1321N1 25 µM 1.5 hours To measure Ca2+ level changes over time, the results showed that MDL29,951 or T0510.3657 compounds could activate the GPR17 receptor and affect intracellular calcium signaling. Sci Rep. 2021 Jan 12;11(1):595
CHO cells 5 μM 60 minutes Evaluate the effect of MDL-29951 on cAMP levels Cell Chem Biol. 2018 Jun 21;25(6):775-786. e5
HEK293 cells 1 μM Evaluate the effect of MDL-29951 on hGPR17 signaling Cell Chem Biol. 2018 Jun 21;25(6):775-786. e5
Primary rat oligodendrocytes 30 μM 48 hours MDL-29951 inhibited MBP expression through GPR17 activation, indicating inhibition of oligodendrocyte differentiation J Biol Chem. 2016 Jan 8;291(2):705-18
Oli-neu cells 10 μM 48 hours MDL-29951 significantly reduced MBP expression levels by activating GPR17, indicating inhibition of oligodendrocyte differentiation J Biol Chem. 2016 Jan 8;291(2):705-18

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
ICR mice LPS-induced cognitive impairment model Microinjection into hippocampal DG region 2.0 μg Daily administration for 3 weeks Activation of hippocampal GPR17 induced cognitive impairment in normal mice J Neuroinflammation. 2023 Nov 21;20(1):271

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.31mL

0.66mL

0.33mL

16.55mL

3.31mL

1.66mL

33.10mL

6.62mL

3.31mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories